1.Applicability Assessment and Comparison of Clinical Reasoning Outputs from General-Purpose Large Language Models in Medical Education
He XU ; Linxuan ZHAI ; Yalun ZHU ; Hengfu CUI ; Zuyi ZHU ; Yang JIAO
Medical Journal of Peking Union Medical College Hospital 2026;17(5):1250-1255
To compare the diagnostic accuracy and differential diagnosis comprehensiveness of six general-purpose large language models (LLMs) on standardized clinical cases, and to assess their applicability for clinical reasoning education. A total of 74 standardized clinical cases published in the Diagnostic accuracy ranged from 62.2% to 78.4% across the six models, with a statistically significant overall difference among models ( Current general-purpose LLMs can achieve a moderate level of diagnostic accuracy on standardized clinical cases, but demonstrate insufficient differential diagnosis comprehensiveness. Given that diagnostic accuracy and differential diagnosis comprehensiveness are fundamental elements of clinical reasoning education, these findings suggest that the quality of LLMs-generated outputs is not yet sufficient for direct application in teaching scenarios and should be used with caution under teacher supervision.
2.SnoRNAs: The promising targets for anti-tumor therapy.
Xiaoyun HU ; Wanlin CUI ; Min LIU ; Fangxiao ZHANG ; Yingqi ZHAO ; Mingrong ZHANG ; Yuhang YIN ; Yalun LI ; Ying CHE ; Xianglong ZHU ; Yuxuan FAN ; Xiaolan DENG ; Minjie WEI ; Huizhe WU
Journal of Pharmaceutical Analysis 2024;14(11):101064-101064
Recently, small nucleolar RNAs (snoRNAs) have transcended the genomic "noise" to emerge as pivotal molecular markers due to their essential roles in tumor progression. Substantial evidence indicates a strong association between snoRNAs and critical clinical features such as tumor pathology and drug resistance. Historically, snoRNA research has concentrated on two classical mechanisms: 2'-O-ribose methylation and pseudouridylation. This review specifically summarizes the novel regulatory mechanisms and functional patterns of snoRNAs in tumors, encompassing transcriptional, post-transcriptional, and post-translational regulation. We further discuss the synergistic effect between snoRNA host genes (SNHGs) and snoRNAs in tumor progression. More importantly, snoRNAs extensively contribute to the development of tumor cell resistance as oncogenes or tumor suppressor genes. Accordingly, we provide a comprehensive review of the clinical diagnosis and treatment associated with snoRNAs and explore their significant potential as novel drug targets.
3.SnoRNAs:The promising targets for anti-tumor therapy
Xiaoyun HU ; Wanlin CUI ; Min LIU ; Fangxiao ZHANG ; Yingqi ZHAO ; Mingrong ZHANG ; Yuhang YIN ; Yalun LI ; Ying CHE ; Xianglong ZHU ; Yuxuan FAN ; Xiaolan DENG ; Minjie WEI ; Huizhe WU
Journal of Pharmaceutical Analysis 2024;14(11):1588-1602
Recently,small nucleolar RNAs(snoRNAs)have transcended the genomic"noise"to emerge as pivotal molecular markers due to their essential roles in tumor progression.Substantial evidence indicates a strong association between snoRNAs and critical clinical features such as tumor pathology and drug resistance.Historically,snoRNA research has concentrated on two classical mechanisms:2'-O-ribose methylation and pseudouridylation.This review specifically summarizes the novel regulatory mecha-nisms and functional patterns of snoRNAs in tumors,encompassing transcriptional,post-transcriptional,and post-translational regulation.We further discuss the synergistic effect between snoRNA host genes(SNHGs)and snoRNAs in tumor progression.More importantly,snoRNAs extensively contribute to the development of tumor cell resistance as oncogenes or tumor suppressor genes.Accordingly,we provide a comprehensive review of the clinical diagnosis and treatment associated with snoRNAs and explore their significant potential as novel drug targets.

Result Analysis
Print
Save
E-mail